Frontlight ResearchEarly access
Active, not recruitingNo phase
Randomized Double-Blind Trial on Safety and Efficacy of Nanordica Advanced Antibacterial Wound Dressing for Diabetic Foot Ulcer
Key facts
- Who runs it
- Nanordica Medical OU
- Where
- Estonia and Spain11 sites in 2 countriesChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 136 people, planned
- Started
- 17 Oct 2024
- Expected to end
- 31 Dec 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Advanced Antibacterial Wound Dressing
- Aquacel Ag+ Extra
- Record updated
- 18 September 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Voluntary, written informed consent obtained prior to any study related activities
- Males and females aged ≥18 years
- DFU(s) present for more than 4 weeks with a maximum diameter of 4 cm
- IWGDF/IDSA Wound infection grades 1 (absent) or 2
- Patients willing and able to comply with scheduled visits, laboratory sampling and study procedures
- Ankle-brachial index (ABI) 0.9-1.4 or ABI between 0.6-0.9 with ankle pressure ≥ 70 mmHg
Who cannot take part
- Ssystemic or topical antibiotic therapy within 7 days before the enrolment
- Previous randomization in this clinical trial
- Surgical procedures in the same leg as the index ulcer(s) (e.g., radical debridement, ulcerectomy, skin grafting, exostectomy, amputation) within the past four weeks, or planned to during the study
- Use of other advanced therapies directly involving the index ulcer(s) (e.g. skin substitutes, matrices, cellbased therapies or products) within the past four weeks
- Patients suffering cardiac disorders grade NYHA IV
- Patients suffering hepatic disorders grade Child-Pugh C
- Stage 4 cancer
- Any wound with known associated osteomyelitis or positive probe-to-bone test
- Women of childbearing potential who are pregnant, breast-feeding or not using adequate contraceptive methods
This trial has no sites in United States.
It has sites in 2 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
This clinical trial evaluates the safety and efficacy of the Nanordica Advanced Antibacterial Wound Dressing (AAWD) in patients suffering from diabetic foot ulcers. At least 136 participants will be randomly allocated to be treated either with AAWD or Aquacel Ag+ Extra wound dressing for a 4-week active phase (intervention) followed by an 8-week standard of care period.
The 2 groups in the trial
- Advanced Antibacterial Wound DressingTreatment being tested
- Aquacel Ag+ ExtraExisting treatment, for comparison
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Randomized, Double Blind, Active Controlled, Parallel Group Clinical Trial to Assess the Safety and Efficacy of Nanordica Antibacterial Wound Dressing in Patients With DFUs
- Record updated
- 18 September 2026